The Science of Neoplasia

  • William B. Ershler


Cancer is a geriatric disease. Over 50% of all cancers occur in the 13% of the population over 65 years old and this population sustains over 60% of all cancer deaths. Neoplastic transformation at the cellular level involves many of the same genetic and molecular pathways as normal cellular senescence. Cell immortalization and senescence reflect contrasting outcomes that involve similar metabolic and molecular pathways. This chapter discusses certain of these common, clinically relevant principles relating cancer and aging. Additionally, an extension of these principles to the topics of cancer prevention and management is presented.


Breast Cancer Familial Adenomatous Polyposis Antigenic Tumor Beta Carotene Natl Cancer Inst 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weinberg RA. Oncogenes and the Molecular Origins of Cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.Google Scholar
  2. 2.
    Korsemeyer SJ. Programmed cell death: Bcl-2. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: JB Lippincott; 1993: 19–28.Google Scholar
  3. 3.
    Nichols J, Nimer SD. Trancription factors, translocation and leukemia. Blood. 1992; 80: 2953–2963.PubMedGoogle Scholar
  4. 4.
    Shields PG, Harris CC. Principles of carcinogenesis: chemical. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 4th ed. Philadephia: JB Lippincott; 1993: 200–212.Google Scholar
  5. 5.
    Meyskens FL. Strategies for prevention of cancer in humans. Oncology. 1992; 6 (suppl 2): 15–24.PubMedGoogle Scholar
  6. 6.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988; 319: 525–532.PubMedCrossRefGoogle Scholar
  7. 7.
    James CD, Carlbom E, Dumanskji JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 1988; 48: 5546–5551.PubMedGoogle Scholar
  8. 8.
    Boyle P, Leake R. Progress in understanding breast cancer: epidemiological and biological interactions. Breast Cancer Res Treat. 1988; 11: 91–112.PubMedCrossRefGoogle Scholar
  9. 9.
    Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer.N Engl J Med. 1992; 327: 319–328, 390–398, 473–480.Google Scholar
  10. 10.
    Carney DN. Biology of small cell lung cancer. Lancet. 1992; 339: 843–846.PubMedCrossRefGoogle Scholar
  11. 11.
    Correa P. Biochemical and molecular methods in cancer epidemiology and prevention: the path between the laboratory and the population. Cancer Epidemiol Biomark Prev. 1993; 2: 85–88.Google Scholar
  12. 12.
    Vineis P. Epidemiological models of carcinogenesis: the example of bladder cancer. Cancer Epidemiol Biomark Prev. 1992; 1: 149–154.Google Scholar
  13. 13.
    El Azouzi M, Chung RY, Farmer GE, et al. Lost of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas. Proc Natl Acad Sei USA. 1989; 86: 7186–7190.CrossRefGoogle Scholar
  14. 14.
    Linehan WM, Gnarra JR, Lerman MI, et al. Genetic bases of renal cell cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: JB Lippincott; 1993: 47–70.Google Scholar
  15. 15.
    Franco EL. Prognostic value of human papillomavirus in the survival of cervical cancer patients: an overview of the evidence. Cancer Epidemiol Biomark Prev. 1992; 1: 499–504.Google Scholar
  16. 16.
    Anisimov VN. Age as a factor of risk in multistage carcinogenesis. In: Balducci L, Lyman GH, Ershler WB, eds. Geriatric Oncology. Philadelphia: JB Lippincott; 1992: 53–60.Google Scholar
  17. 17.
    Fernandez-Pol JA. Growth factors, oncogenes, antionco-genes and aging. In: Balducci L, Lyman GH, Ershler WB, eds. Geriatric Oncology. Philadelphia: JB Lippincott; 1992: 76–85.Google Scholar
  18. 18.
    Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988; 319: 1047–1052.PubMedCrossRefGoogle Scholar
  19. 19.
    Anisimov VN. Effect of age on dose-response relationship in carcinogenesis induced by single administration of N-methynitrosourea in female rats. J Cancer Res Clin Oncol. 1988; 114: 628–635.PubMedCrossRefGoogle Scholar
  20. 20.
    Ward JM, Lynch P, Riggs C. Rapid development of hepatocellular neoplasms in aging male C3H/HeNcr mice given phénobarbital. Cancer Eett. 1988; 39: 9–18.Google Scholar
  21. 21.
    Ebbesen P. Reticulosarcoma and amyloid development in BALB/c mice inoculated with syngeneic cells from young and old donors. J Natl Cancer Inst. 1971; 47: 1241–1245.PubMedGoogle Scholar
  22. 22.
    Anisimov VN, Loktionov AS, Khavinson VK, Morozov VG. Effect of low molecular weight factors of thymus and pineal gland on life span and spontaneous tumor development in female mice of different age. Mech Ageing Dev. 1989; 49: 245–257.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaldor JM, Day NE. Interpretation of epidemiological studies in the context of the multistage model of carcinogenesis. In: Barrett JC, ed. Mechanisms of Environmental Carcinogenesis, vol 2. Boca Raton: CRC Press; 1987: 21–57.Google Scholar
  24. 24.
    Tantranond P, Karam F, Wang TY, et al. Management of cutaneous squamous cell carcinoma in an elderly man. J Am Geriatr Soc. 1992; 40: 510–512.PubMedGoogle Scholar
  25. 25.
    Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell carcinoma of the skin. JAMA. 1989; 262: 2097–2100.PubMedCrossRefGoogle Scholar
  26. 26.
    Matoha MF, Cosgrove JW, Atak JR, Rappoport SI. Selective elevation of the c-myc transcript levels in the liver of the aging Fischer 344 rat. Biochem Biophys Res Commun. 1987; 147: 1–7.CrossRefGoogle Scholar
  27. 27.
    Bohr VA, Evans MK, Fornace AJ. Biology of disease: DNA repair and its patogenetic implications. Lab Invest 1989; 61: 143–161.PubMedGoogle Scholar
  28. 28.
    Balducci L, Wallace C, Khansur T, et al. Aging, nutrition and cancer, an annotated review. I- Diet, carcinogenesis and aging. J Am Geriatr Soc. 1986; 34: 127–136.PubMedGoogle Scholar
  29. 29.
    Randerath K, Reddy MV, Disher RM. Age-and tissue-related DNA modifications in untreated rats: detection by 32P-post-labeling assay and possible significance for spontaneous tumor induction and aging. Carcinogenesis. 1986; 7: 1615–1617.PubMedCrossRefGoogle Scholar
  30. 30.
    Ershler WB. The influence of an aging immune system on cancer incidence and progression. J Gerontol. 1993; 48: B3- B7.PubMedCrossRefGoogle Scholar
  31. 31.
    Miller RA. Aging and cancer: another perspective. J Gerontol. 1993; 48: B8 - B10.PubMedCrossRefGoogle Scholar
  32. 32.
    Covelli V, Mouton D, Majo V, et al. Inheritance of immune responsiveness, life span and disease incidence in interline crosses of mice selected for high or low multispecific antibody production. J Immunol. 1989; 142: 1224–1234.PubMedGoogle Scholar
  33. 33.
    Ershler WB, Stewart JA, Hacker MP, Moore AL, Tindle BH. B16 murine melanoma and aging: slower growth and longer survival in old mice. J Natl Cancer Inst. 1984; 72: 161–165.PubMedGoogle Scholar
  34. 34.
    Ershler WB, Moore AL, Shore H, Gameiii RL. Transfer of age-associated restrained tumor growth in mice by old to young bone marrow transplantation. Cancer Res. 1984; 44: 5677–5681.PubMedGoogle Scholar
  35. 35.
    Tsuda T, Kim YT, Siskind GW, et al. Role of the thymus and T-cells in slow growth of B16 melanoma in old mice. Cancer Res. 1987; 47: 3097–3103.PubMedGoogle Scholar
  36. 36.
    Ershler WB. Guest editorial: Why tumors grow more slowly in old people. J Natl Cancer Inst. 1986; 77: 837–839.PubMedGoogle Scholar
  37. 37.
    Simon SR, Ershler WB. Hormonal influences on growth of B16 murine melanoma. J Natl Cancer Inst. 1985; 74: 1085–1088.PubMedGoogle Scholar
  38. 38.
    Ershler WB, Berman E, Moore AL. B16 melanoma growth is slower, but pulmonary colonization is greater in calorie restricted mice. J Natl Cancer Inst. 1986; 76: 81–85.PubMedGoogle Scholar
  39. 39.
    Ershler WB, Gamelli RL, Moore AL, Hacker MP, Blow AJ. Experimental tumors and aging: local factors that may account for the observed age advantage in the B16 murine melanoma model. Exp Gerontol. 1984; 19: 367–375.PubMedCrossRefGoogle Scholar
  40. 40.
    Hadar E, Ershler WB, Kreisle RA, Ho S-P, Volk MJ, Klopp RG. Lymphocyte-induced angiogenesis factor is produced by L3T4+ murine T lymphocytes, and its production declines with age. Cancer Immunol Immunother. 1988; 26: 31–37.PubMedCrossRefGoogle Scholar
  41. 41.
    Kreisle RA, Stebler B, Ershler WB. Effect of host age on tumor associated angiogenesis in mice. J Natl Cancer Inst. 1990; 82: 44–47.PubMedCrossRefGoogle Scholar
  42. 42.
    Fidler IJ, Gersten DM, Riggs CW. Relationship of host immune status to tumor cell arrest, distribution and survival in experimental metastases. Cancer. 1977; 40: 46–55.PubMedCrossRefGoogle Scholar
  43. 43.
    Prehn RT, Lappe MA. An immunostimulation theory of tumor development. Transplant Rev. 1971; 7: 26–30.PubMedGoogle Scholar
  44. 44.
    Prehn RT. The immune reaction as a stimulator of tumor growth. Science. 1972; 176: 170–175.PubMedCrossRefGoogle Scholar
  45. 45.
    Schiede C, Elkins D, Mason D, et al. Influence of age on smoking cessation. J Am Geriatr Soc. 1992; 40: SA3.Google Scholar
  46. 46.
    Kelloff GJ, Malone WF, Boone CW. Progress in applied chemoprevention research. Semin Oncol. 1990; 17: 438–455.PubMedGoogle Scholar
  47. 47.
    Buring JE, Hennekens CH. Cancer prevention: retinoids and carotenoids. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 4th ed. Philadelphia: JB Lippincott; 1993: 464–474.Google Scholar
  48. 48.
    Hong WL, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinine in squamous cell carcinoma of the head and neck. N Engl J Med. 1990; 323: 725–731.CrossRefGoogle Scholar
  49. 49.
    Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene, to prevent oral carcinogenesis. TV Engl J Med. 1993; 328: 15–20.CrossRefGoogle Scholar
  50. 50.
    Alpha Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994; 330: 1029–1035.Google Scholar
  51. 51.
    Hennekens CH, Buring JE, Peto R. Antioxidant vitamins—benefits not yet proved. N Engl J Med. 1994; 330: 1080–1081.PubMedCrossRefGoogle Scholar
  52. 52.
    Ballmer PE, Stahelin HB. Beta carotene, vitamin E and lung cancer. N Engl J Med. 1994; 331: 612–613.Google Scholar
  53. 53.
    Goldstein MR. Beta carotene, vitamin E and lung cancer. N Engl J Med. 1994; 331: 612.Google Scholar
  54. 54.
    Jordan VC. Estrogen receptor mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst. 1990; 82: 1662–1663.PubMedCrossRefGoogle Scholar
  55. 55.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992; 339: 1–15, 71–85.Google Scholar
  56. 56.
    Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991; 83: 1450–1459.PubMedCrossRefGoogle Scholar
  57. 57.
    Love R, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991; 115: 860–864.PubMedGoogle Scholar
  58. 58.
    Love R, Mazess RB, Barden SH. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992; 326: 852–856.PubMedCrossRefGoogle Scholar
  59. 59.
    Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary pyroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 1987; 47: 5340–5346.PubMedGoogle Scholar
  60. 60.
    Metzger U, Meier J, Ulschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH induced rat colon cancer. Dis Colon Rectum. 1984; 27: 366–369.PubMedCrossRefGoogle Scholar
  61. 61.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991; 101: 635–639.PubMedGoogle Scholar
  62. 62.
    Greenberg ER, Baron JA, Freeman DH, et al. Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst. 1993; 85: 912–916.PubMedCrossRefGoogle Scholar
  63. 63.
    Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: non steroidal antiinflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991; 83: 355–358.PubMedCrossRefGoogle Scholar
  64. 64.
    Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991; 325: 1593–1596.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • William B. Ershler

There are no affiliations available

Personalised recommendations